Premium
Comparison of a new pmp22 transgenic mouse line with other mouse models and human patients with CMT1A *
Author(s) -
Robertson A. M.,
Perea J.,
McGuigan A.,
King R. H. M.,
Muddle J. R.,
GabreëlsFesten A. A.,
Thomas P. K.,
Huxley C.
Publication year - 2002
Publication title -
journal of anatomy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.932
H-Index - 118
eISSN - 1469-7580
pISSN - 0021-8782
DOI - 10.1046/j.1469-7580.2002.00039.x
Subject(s) - peripheral myelin protein 22 , genetically modified mouse , myelin , transgene , point mutation , biology , gene , phenotype , gene duplication , peripheral nervous system , mutation , peripheral neuropathy , gene knockin , pathology , genetics , neuroscience , medicine , central nervous system , endocrinology , diabetes mellitus
Charcot‐Marie‐Tooth disease type 1A is a dominantly inherited demyelinating disorder of the peripheral nervous system. It is most frequently caused by overexpression of peripheral myelin protein 22 (PMP22), but is also caused by point mutations in the PMP22 gene. We describe a new transgenic mouse model (My41) carrying the mouse, rather than the human, pmp22 gene. The My41 strain has a severe phenotype consisting of unstable gait and weakness of the hind limbs that becomes obvious during the first 3 weeks of life. My41 mice have a shortened life span and breed poorly. Pathologically, My41 mice have a demyelinating peripheral neuropathy in which 75% of axons do not have a measurable amount of myelin. We compare the peripheral nerve pathology seen in My41 mice, which carry the mouse pmp22 gene, with previously described transgenic mice over‐expressing the human PMP22 protein and Trembler‐ J (Tr J ) mice which have a P16L substitution. We also look at the differences between CMT1A duplication patients, patients with the P16L mutation and their appropriate mouse models.